Thus, combination of antibody-mediated immunotherapy with TLR2 targeting could represent an opportunity to improve NK cell cytotoxicity, which is frequently impaired in HNSCC patients, resulting in enhanced anti-tumor immune responses. The gene discussed is TLR2; the disease is head and neck squamous cell carcinoma.